Preclinical Pharmacokinetics and In Vitro Metabolism of Asunaprevir (BMS‐650032), a Potent Hepatitis C Virus NS3 Protease Inhibitor

Publisher： John Wiley & Sons Inc

E-ISSN： 1520-6017|104|9|2813-2823

ISSN： 0022-3549

Source： JOURNAL OF PHARMACEUTICAL SCIENCES (ELECTRONIC), Vol.104, Iss.9, 2015-09, pp. : 2813-2823

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Synthesis of deleobuvir, a potent hepatitis C virus polymerase inhibitor, and its major metabolites labeled with carbon‐13 and carbon‐14

JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS (ELECTRONIC), Vol. 58, Iss. 6, 2015-05 ,pp. : 250-260

John Wiley & Sons Inc

Access to resources Recommend Favorite

P2‐Quinazolinones and Bis‐Macrocycles as New Templates for Next‐Generation Hepatitis C Virus NS3/4a Protease Inhibitors: Discovery of MK‐2748 and MK‐6325

CHEMMEDCHEM, Vol. 10, Iss. 4, 2015-04 ,pp. : 727-735

John Wiley & Sons Inc

Access to resources Recommend Favorite

Formal Synthesis of the Human Rhinovirus 3 C Protease Inhibitor (−)‐Thysanone

ASIAN JOURNAL OF ORGANIC CHEMISTRY, Vol. 4, Iss. 6, 2015-06 ,pp. : 560-566

John Wiley & Sons Inc

Access to resources Recommend Favorite

Analysis of the Resistance of Hepatitis C Virus NS5B Polymerase Inhibitors via Docking and Molecular Dynamics Simulation

MOLECULAR INFORMATICS, Vol. 34, Iss. 2‐3, 2015-02 ,pp. : 78-83

John Wiley & Sons Inc

Access to resources Recommend Favorite

Management of patients with hepatitis C virus resistance–associated variants to NS5A inhibitors: Where are we now?

CLINICAL LIVER DISEASE (ELECTRONIC), Vol. 6, Iss. 4, 2015-10 ,pp. : 82-85

John Wiley & Sons Inc

Access to resources Recommend Favorite